127 related articles for article (PubMed ID: 11154621)
1. Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine.
Longhurst HJ; Pinching AJ
BMJ; 2001 Jan; 322(7278):81. PubMed ID: 11154621
[No Abstract] [Full Text] [Related]
2. Extended warning on Didanosine-related pancreatitis.
Res Initiat Treat Action; 1999 Dec; 5(5):22-3. PubMed ID: 11366889
[TBL] [Abstract][Full Text] [Related]
3. ddI, d4T, Hydroxyurea: new pancreatitis warning.
AIDS Treat News; 1999 Nov; (No 331):1-3. PubMed ID: 11367125
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine.
Luzzati R; Di Perri G; Fendt D; Ramarli D; Broccali G; Concia E
J Antimicrob Chemother; 1998 Oct; 42(4):565-6. PubMed ID: 9818769
[No Abstract] [Full Text] [Related]
5. Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
Barreiro P; Soriano V; Valencia E; Díaz B; González-Lahoz J
AIDS; 2001 Dec; 15(18):2469-70. PubMed ID: 11774839
[No Abstract] [Full Text] [Related]
6. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.
Lori F; Foli A; Groff A; Lova L; Whitman L; Bakare N; Pollard RB; Lisziewicz J
AIDS; 2005 Jul; 19(11):1173-81. PubMed ID: 15990570
[TBL] [Abstract][Full Text] [Related]
7. Is Hydroxyurea for real?
Mascolini M
J Int Assoc Physicians AIDS Care; 1998 Aug; 4(8):6-16, 18. PubMed ID: 11365731
[TBL] [Abstract][Full Text] [Related]
8. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
9. Excess peripheral neuropathy in patients treated with hydroxyurea plus didanosine and stavudine for HIV infection.
Cepeda JA; Wilks D
AIDS; 2000 Feb; 14(3):332-3. PubMed ID: 10716516
[No Abstract] [Full Text] [Related]
10. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on didanosine therapy.
Allaouchiche B; Duflo F; Cotte L; Mathon L; Chassard D
J Antimicrob Chemother; 1999 Jul; 44(1):137-8. PubMed ID: 10459826
[No Abstract] [Full Text] [Related]
11. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic warning for ddI.
AIDS Patient Care STDS; 2000 Feb; 14(2):101. PubMed ID: 10743523
[No Abstract] [Full Text] [Related]
13. Hydroxyurea-induced nail pigmentation in HIV patients.
Joyner S; Lee D; Hay P; Lau R
HIV Med; 1999 Oct; 1(1):40-2. PubMed ID: 11737328
[TBL] [Abstract][Full Text] [Related]
14. Hydroxyurea-induced neurotoxicity in HIV disease.
Barry M; Clarke S; Mulcahy F; Back D
AIDS; 1999 Aug; 13(12):1592-4. PubMed ID: 10465092
[No Abstract] [Full Text] [Related]
15. Acute onset of pancreatitis with concomitant use of tenofovir and didanosine.
Kirian MA; Higginson RT; Fulco PP
Ann Pharmacother; 2004 Oct; 38(10):1660-3. PubMed ID: 15340130
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.
Martínez E; Milinkovic A; de Lazzari E; Ravasi G; Blanco JL; Larrousse M; Mallolas J; García F; Miró JM; Gatell JM
Lancet; 2004 Jul 3-9; 364(9428):65-7. PubMed ID: 15234858
[TBL] [Abstract][Full Text] [Related]
17. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
[TBL] [Abstract][Full Text] [Related]
18. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy.
Butt AA
AIDS Read; 2003 Jul; 13(7):344-8. PubMed ID: 12889452
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
Seminari E; Lisziewicz J; Tinelli C; Foli A; Lori F; Maserati R
Int J Clin Pharmacol Ther; 1999 Oct; 37(10):514-8. PubMed ID: 10543320
[TBL] [Abstract][Full Text] [Related]
20. Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.
Foli A; Lori F; Maserati R; Tinelli C; Minoli L; Lisziewicz J
Antivir Ther; 1997 Jan; 2(1):31-8. PubMed ID: 11322264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
